Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rong Pan

Showing results (361-370 of 367) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 367 results.
Nature Communications|April 30, 2024
Cost-effectiveness and cost-utility of a digital technology-driven hierarchical healthcare screening pattern in ChinaXiaohang Wu, Yuxuan Wu, Zhenjun Tu, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of an Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
The New England Journal of Medicine|March 5, 2015
Long-term efficacy of a hepatitis E vaccineJun Zhang, Xue-Feng Zhang, Shou-Jie Huang, et al.
The Lancet. Infectious Diseases|July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trialFeng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Advances|March 21, 2020
An array of 60,000 antibodies for proteome-scale antibody generation and target discoveryZhaohui Wang, Yang Li, Bing Hou, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute|May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialYou-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Pageof 37

Showing results (361-370 of 367) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 367 results.
Nature Communications|April 30, 2024
Cost-effectiveness and cost-utility of a digital technology-driven hierarchical healthcare screening pattern in ChinaXiaohang Wu, Yuxuan Wu, Zhenjun Tu, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of an Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
The New England Journal of Medicine|March 5, 2015
Long-term efficacy of a hepatitis E vaccineJun Zhang, Xue-Feng Zhang, Shou-Jie Huang, et al.
The Lancet. Infectious Diseases|July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trialFeng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Advances|March 21, 2020
An array of 60,000 antibodies for proteome-scale antibody generation and target discoveryZhaohui Wang, Yang Li, Bing Hou, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute|May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialYou-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Pageof 37